PLRZ
Polyrizon Ltd.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Strong sell
-69/100
Last price
9.28
▼ 0.07 (0.75%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
9.69
Prev close
9.35
Day high
9.67
Day low
9.26
Volume
5.23K
Market cap
$23.48M
P/E (TTM)
—
52W range
2.88 – 18.20
Day trading desk
Gap from prior close
+4.64%
Prior close 9.26
VWAP
9.33
-0.58% from price
Relative volume
0.08×
Quiet session
Session range
9.35%
9.20 – 10.06
Position in range
9%
Near session low
ATR (14D)
0.89
9.63% of price
Prior day high
9.88
PDH
Prior day low
9.13
PDL
Bid / ask spread
—
Quote not published
Session volume
5.23K
Avg 62.19K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-7.82%
-9.8%
1M
-13.97%
-15.1%
3M
-33.81%
-38.3%
6M
-12.73%
-30.9%
YTD
+13.90%
-0.4%
1Y
+47.86%
+31.4%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PLRZ open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
15.41K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Mar 31, 26 | CARMEL LIRON Director |
SELL | 942 | $11.64K | Direct |
| Mar 31, 26 | IZRAELI TOMER Chief Executive Officer |
SELL | 500 | $5.92K | Direct |
| Mar 31, 26 | ADLER OZ Director |
SELL | 3.29K | $39.67K | Direct |
| Mar 30, 26 | CARMEL LIRON Director |
SELL | 100 | $1.10K | Direct |
| Mar 30, 26 | TURGEMAN TIDHAR Chief Technology Officer |
SELL | 2.92K | $31.80K | Direct |
| Mar 30, 26 | IZRAELI TOMER Chief Executive Officer |
SELL | 3.90K | $42.51K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ADLER OZ |
Director | 19.85K | Sale |
CARMEL LIRON |
Director | 3.13K | Sale |
IZRAELI TOMER |
Chief Executive Officer | 31.51K | Sale |
TURGEMAN TIDHAR |
Chief Technology Officer | 17.52K | Sale |
Fundamentals
Market cap$23.48M
Enterprise value$4.48M
Revenue (TTM)—
Gross profit—
EBITDA$-7.82M
Net income$-4.58M
EPS (TTM)$-5.19
Free cash flow$-2.09M
Total cash$16.07M
Total debt$0
Book value / share$11.49
Shares outstanding2.43M
Float1.87M
Short % of float2.37%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book0.84
EV / revenue—
EV / EBITDA-0.57
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-21.42%
Return on assets-23.30%
Debt / equity—
Current ratio36.37
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $2.13M | $534.00K | $332.00K | $347.00K | +299.4% |
| Selling, general & admin | $3.65M | $768.00K | $303.00K | $548.00K | +375.5% |
| Total operating expense | $5.79M | $1.30M | $635.00K | $895.00K | +344.3% |
| Operating income | -$5.79M | -$1.30M | -$635.00K | -$895.00K | -344.3% |
| Net interest income | -$2.77M | -$28.00K | -$230.00K | $24.00K | -9,803.6% |
| Pre-tax income | -$3.33M | -$1.54M | -$600.00K | -$779.00K | -115.9% |
| Net income | -$3.33M | -$1.54M | -$600.00K | -$779.00K | -115.9% |
| Net income to common | -$3.33M | -$1.60M | -$669.00K | -$823.00K | -107.8% |
| Basic EPS | — | -805.20 | -239.27 | -294.35 | — |
| Diluted EPS | — | -805.20 | -239.27 | -294.35 | — |
| EBIT | -$5.79M | -$1.30M | -$635.00K | -$895.00K | -344.3% |
| EBITDA | -$5.44M | -$1.18M | -$631.00K | -$890.00K | -359.7% |
| Basic shares | — | 1.99K | 2.80K | 2.80K | — |
| Diluted shares | — | 1.99K | 2.80K | 2.80K | — |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.31M | $2.55M | $4.00K | $36.00K | -48.9% |
| Cash & short-term investments | $12.46M | $2.55M | $41.00K | $36.00K | +388.0% |
| Total current assets | $12.86M | $2.65M | $54.00K | $51.00K | +384.7% |
| Property, plant & equipment | $12.00K | $10.00K | $12.00K | $16.00K | +20.0% |
| Goodwill & intangibles | $2.55M | $2.88M | $0 | — | -11.7% |
| Total assets | $21.44M | $5.55M | $559.00K | $546.00K | +286.5% |
| Total current liabilities | $443.00K | $261.00K | $502.00K | $1.20M | +69.7% |
| Current debt | — | — | $200.00K | $622.00K | — |
| Total debt | — | — | $200.00K | $622.00K | — |
| Total liabilities | $443.00K | $261.00K | $750.00K | $1.45M | +69.7% |
| Retained earnings | -$8.40M | -$5.07M | -$3.52M | -$2.92M | -65.8% |
| Shareholder equity | $20.99M | $5.29M | -$191.00K | -$900.00K | +297.2% |
| Working capital | $12.42M | $2.39M | -$448.00K | -$1.15M | +419.1% |
| Net tangible assets | $18.45M | $2.40M | -$191.00K | -$900.00K | +668.0% |
| Shares issued | 1.61M | 2.80K | 2.80K | 2.80K | +57,420.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$3.33M | -$1.54M | -$600.00K | -$779.00K | -115.9% |
| Depreciation & amortisation | $342.00K | $118.00K | $4.00K | $5.00K | +189.8% |
| Stock-based compensation | $1.31M | $51.00K | $100.00K | $130.00K | +2,468.6% |
| Change in working capital | -$158.00K | -$21.00K | $7.00K | -$344.00K | -652.4% |
| Operating cash flow | -$4.53M | -$1.15M | -$537.00K | -$1.13M | -294.8% |
| Capital expenditure | -$7.00K | — | — | -$3.00K | — |
| Investing cash flow | -$16.53M | $29.00K | $0 | -$3.00K | -57,113.8% |
| Financing cash flow | $19.81M | $3.67M | $505.00K | $648.00K | +440.2% |
| Free cash flow | -$4.54M | -$1.15M | -$537.00K | -$1.14M | -295.4% |
| End cash position | $1.31M | $2.55M | $4.00K | $36.00K | -48.9% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|
| Cash & equivalents | $1.31M | $15.83M | -91.7% |
| Cash & short-term investments | $12.46M | $15.83M | -21.3% |
| Total current assets | $12.86M | $16.03M | -19.8% |
| Property, plant & equipment | $12.00K | $10.00K | +20.0% |
| Goodwill & intangibles | $2.55M | $2.70M | -5.6% |
| Total assets | $21.44M | $18.74M | +14.4% |
| Total current liabilities | $443.00K | $364.00K | +21.7% |
| Total liabilities | $443.00K | $364.00K | +21.7% |
| Retained earnings | -$8.40M | -$5.24M | -60.2% |
| Shareholder equity | $20.99M | $18.38M | +14.3% |
| Working capital | $12.42M | $15.67M | -20.7% |
| Net tangible assets | $18.45M | $15.68M | +17.7% |
| Shares issued | 1.61M | 980.13K | +64.1% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.73%
Held by institutions9.35%
Institutions holding5
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
10.29
-9.85% from price
SMA 20
10.64
-9.15% from price
SMA 50
11.11
-12.99% from price
SMA 100
12.34
-24.81% from price
SMA 200
12.77
-24.27% from price
EMA 12
10.27
-9.63% from price
EMA 26
10.77
-13.80% from price
EMA 50
11.29
-17.81% from price
RSI (14)
40.0
Neutral
MACD (12,26,9)
-0.50
Hist -0.12
ATR (14)
0.89
9.24% of price
Realised vol 30D
84.4%
Annualised
Bollinger upper
11.77
20, 2σ
Bollinger lower
9.52
20, 2σ
50 / 200 cross
Death
11.11 vs 12.77
Trend bias
Below 200
-24.27%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.26
More volatile than market
Correlation to SPY
0.08
Largely independent
Realised vol 30D
84.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-58.2%
Peak to trough
Max drawdown 5Y
-99.9%
Peak to trough
ATR 14
0.89
9.24% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
55.52K
Prior 94.22K
Change vs prior
-41.1%
Shorts covering
% of float
2.37%
Normal
% of shares out
2.34%
Against total outstanding
Days to cover
0.6
Liquid
Float
1.87M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:6
Split dateNov 28, 2025
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-10-05
Offering Registrations
F-1/A · 2026-09-28
Offering Registrations
F-1 · 2026-09-18
Additional Forms
D · 2026-09-10
Corporate Changes & Voting Matters
6-K · 2026-08-20
Corporate Changes & Voting Matters
6-K · 2026-07-13
Corporate Changes & Voting Matters
6-K · 2026-07-02
Corporate Changes & Voting Matters
6-K · 2026-06-29
Headlines
Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform
GlobeNewswire · 2d ago
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
GlobeNewswire · 15d ago
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
GlobeNewswire · 33d ago
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement
GlobeNewswire · 34d ago
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study
GlobeNewswire · 35d ago
Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment
GlobeNewswire · 48d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.